NCT02378844已完成不适用
A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 477
- 试验地点
- 44
- 主要终点
- Change in the Number of Migraine Days
研究概览
简要总结
A prospective, double-blind, randomized, sham-controlled, multicentre investigation.
详细描述
The study period will begin with a four week run-in period, during which there is no investigational treatment. The purpose of the run-in period will be observation for baseline comparison.
The run-in period will be, followed by a 12 week randomized period when the subjects will be randomized (1:1) to either active treatment or sham (inactive) treatment.
The randomized period will be followed by a 24 week open label period, where the subjects in the sham treatment group will switch in treatment assignment and receive a gammaCore®-R and the gammaCore®-R will continue to receive an active treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is between the ages of 18 and 75 years.
- •Has been previously diagnosed with migraine (with or without aura) in accordance with the International Classification of Headache Disorders (ICHD)-3 Beta Classification criteria.
- •Experience between 5 and 12 migraine days per month (over the last 4 months) with at least 2 of the migraines lasting more than 4 hours.
- •Has age of onset of migraine less than 50 years old.
- •Agrees not to use any migraine prevention treatments (including Botox injections) and/or medications (exclusive of medications taken for acute relief of migraine symptoms).
- •Agrees to refrain from initiating or changing the type, dosage or frequency of any prophylactic medications for indications other than migraine that in the opinion of the clinician may interfere with the study objectives (e.g. antidepressant, anti convulsant, beta blockers, etc.).
- •Agrees to use the gammaCore®-R device as intended, follow all of the requirements of the study including follow-up visit requirements, record required study data in the subject dairy, and other self-assessment questionnaires.
- •Is able to provide written Informed Consent.
排除标准
- •Has a concomitant medical condition that will require oral or injectable steroids during the study.
- •Has a history of any intracranial aneurysm, intracranial haemorrhage, brain tumour or significant head trauma.
- •Has a structural abnormality at the gammaCore®-R treatment site (e.g lymphadenopathy previous surgery or abnormal anatomy).
- •Has pain at the gammaCore®-R treatment site (e.g.dysesthesia, neuralgia and/or cervicalgia).
- •Has other significant pain problem (e.g.cancer pain, fibromyalgia or other head or facial disorder) that in the opinion of the investigator may confound the study assessments
- •Has know or suspected severe cardiac disease(e.g. symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure (CHF)).
- •Has known or suspected severe cerebrovascular disease, (e.g. prior stroke or transient ischemic attack, symptomatic carotid artery disease, prior carotid endarterectomy or other vascular neck surgery).
- •Has an abnormal baseline Electrocardiogram (ECG) e.g. second and third degree heart block, prolonged QT interval, atrial fibrillation, atrial flutter, history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction).
- •Has had a cervical vagotomy.
- •Has uncontrolled high blood pressure (systolic >160 diastolic > 100 after 3 repeated measurements within 24 hours).
- •Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion stimulator or Occipital nerve stimulator).
- •Has been implanted with metal cervical spine hardware or has a metallic implant near the gammaCore®-R stimulation site.
- •Has a known history of suspicion of secondary headache.
- •Has a history of syncope (within the last five years).
- •Has a history of seizures (within the last five years).
- •Has a known or suspicion of substance abuse or addiction (within the last 5 years).
- •Is using marijuana (including medical marijuana) for any indications, more than twice a month.
- •Currently takes simple analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) greater than 15 days per month or triptans, ergots or combined analgesics greater than 10 days per month for headaches or other body pain.
- •Currently takes prescription opioids greater than 2 days per month for headaches or body pain.
- •Has taken medications for migraine prophylaxis in the previous 30 days.
- •Has previous diagnosis of medication overuse headache (MoH) , which has reverted to episodic migraine within the last 6 months.
- •Meets the ICHD-3 Beta Classification criteria for chronic migraine (> 15 headache days per month).
- •Has failed an adequate trial (two months or greater) of at least 3 classes of a drug therapy for the prophylaxis of migraine .
- •Has had surgery for migraine prevention.
- •Has undergone nerve block (occipital or other) in the head or neck within the last 2 months.
- •Has received Botox injections within the last 6 months.
- •Is pregnant or thinking of becoming pregnant during the study period, or of childbearing years and is unwilling to use and accepted form of birth control.
- •Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
- •Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with the follow-up requirements, or provide self- assessments is compromised (e.g. homeless, developmentally disabled and prisoner).
- •Is a relative of or an employee of the investigator or the clinical study site.
- •Has psychiatric or cognitive disorder and/or behavioural problems which in the opinion of the clinician may interfere with the study.
- •Has previously used the gammaCore® device.
研究组 & 干预措施
gammaCore®-R
Active Comparator
Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
干预措施: gammaCore®-R (Device)
gammaCore®-R Sham
Sham Comparator
Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
干预措施: gammaCore®-R Sham (Device)
结局指标
主要结局
Change in the Number of Migraine Days
时间窗: last 4 weeks of the randomized/controlled period compared to the subject's own 4-week run-in period.
Change in number of migraine days (as reported in subject diary), comparing the 4 week run-in period to the last 4 weeks in the randomized period.
次要结局
- Number of Participants With 50% Responder Rate(The last four weeks in the randomization period compared to the four week run-in period.)
- Number of Participants With Adverse Events(up to Week 36)
- Change in Headache Disability Using Headache Impact Test-6(From four week run-in period to last four weeks in the randomization period)
- Mean Change in Number of Headache Days(The last four weeks in the randomization period compared to the four week run-in period.)
- Change in Number of Acute Medication Days(The last four weeks in the randomization period compared to the four week run-in period.)
- Compare Changes in Quality of Life EuroQol Questionnaire 5 Dimensions and 5 Levels (EQ-5D-5L)(From four week run-in period to last four weeks in the randomization period)
- Change in Headache Days in the Open Label Period(The 6 month open-label period compared to the four week run-in period)
- Number of Participants According to Grade on the Migraine Disability Assessment (MIDAS) Before and After Randomized Period(3 months - end of run-in period to end of randomized period)
- Change in Migraine Days in the Open Label Period (Adjusted ANCOVA)(The 6 month open-label period compared to the four week run-in period)
研究者
研究点 (44)
Loading locations...
相似试验
Unknown
不适用
Safety and Nutritional Adequacy of a New Infant Formula in Healthy Term InfantsChild DevelopmentNCT04013087Heilongjiang Feihe Dairy Co. Ltd.450
Unknown
不适用
The Effect of a New Infant Formula on Growth and Cognition in Healthy Term InfantsChild DevelopmentNCT04508257Heilongjiang Feihe Dairy Co. Ltd.450
已完成
不适用
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine AttacksMigraineNCT02686034ElectroCore INC285
已完成
不适用
RHA® 3 Versus Restylane-L® for Lip AugmentationLip AugmentationLipNCT04540913Teoxane SA202
已完成
不适用
A Clinical Trial to Evaluate the Vision Correction Safety and Efficacy of MSiHy Silicone Hydrogel Soft Contact LensRefractive ErrorsMyopiaNCT06716385Visco Vision Inc.134